^
    3d
    Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. (PubMed, Kidney Med)
    Daratumumab-based induction therapy resulted in a partial renal response (urinary protein-creatinine ratio of 0.7 g/g)...To our knowledge, this case represents only the second reported case of HTRA1-MN occurring in the setting of monoclonal gammopathy, the first in multiple myeloma, and a rare example of a nonmonotypic MN in this context. Temporal proximity and partial response to anti-plasma cell therapy suggest a possible paraneoplastic relationship, although a causal relationship remains unproven.
    Journal
    |
    HTRA1 (HtrA Serine Peptidase 1)
    |
    Darzalex (daratumumab)
    7d
    ALLG MM21: Daratumumab-lenalidomide-dexamethasone (DRd) salvage for newly diagnosed Multiple Myeloma patients who fail bortezomib induction therapy (ACTRN12618001490268)
    P2, N=50, Completed, Australiasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    8d
    EMN2868284528MMY3005: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (2023-507632-20-00)
    P2/3, N=440, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Carvykti (ciltacabtagene autoleucel)
    9d
    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    10d
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    13d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)
    13d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    15d
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 (clinicaltrials.gov)
    P3, N=255, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • pomalidomide
    16d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB | N=38 --> 153
    Enrollment change
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    16d
    A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (clinicaltrials.gov)
    P1/2, N=199, Recruiting, AbbVie | N=130 --> 199
    Enrollment change • Adverse events
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • surzetoclax (ABBV-453)
    17d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Oct 2026 --> Aug 2028 | Trial primary completion date: Apr 2026 --> Aug 2028
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    clonoSEQ®
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    18d
    2023/ABM/01/00072: A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) (2024-513917-11-01)
    P1/2, N=36, Not yet recruiting, Uniwersytet Medyczny W Lublinie
    New P1/2 trial
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Darzalex (daratumumab)